Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | CASP4 | P49662 | 1/20 | 0.61 |
| ▸ | CASP5 | P51878 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | CASP9 | P55211 | 1/20 | 0.61 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.61 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.61 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 8/20 | 0.41 |
| ▸ | STAT5A | P42229 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | STAT5B | P51692 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12023624 | 1.00 | CASP1 (0.67) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL30628927 | 0.93 | CASP1 (0.66) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL12266522 | 0.91 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL12266527 | 0.91 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL3469989 | 0.90 | CASP1 (0.55) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL3471227 | 0.90 | CASP1 (0.55) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL20298320 | 0.89 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL3058685 | 0.89 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL3699919 | 0.89 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 | |
| SCHEMBL478382 | 0.89 | CASP1 (0.68) | CASP1CASP4CASP5CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-02-13 | — | — | US | disclosed |
| US-9994613-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2017-01-26 | — | — | US | disclosed |
| US-9487555-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-08 | — | — | US | disclosed |
| US-9156880-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-08 | — | — | US | disclosed |
| EP-2270005-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20130331310-A1 | Prodrug of an Ice Inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2013-12-12 | — | — | US | disclosed |
| US-8329662-B2 | Prodrug of an ICE inhibitor | Vertexd Pharmaceuticals Incorporated (US) | 2012-12-11 | — | — | US | disclosed |
| EP-1396492-B1 | Prodrug of an ice inhibitor | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1286989-B1 | Prodrug of an ICE inhibitor | VERTEX PHARMA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-08 | — | — | US | disclosed |
| US-8022041-B2 | Prodrug of an ICE inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2270005-A1 | Prodrug of an ice inhibitor | Vertex Pharmceuticals Incorporated (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-7417029-B2 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1396492-A1 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1286989-A2 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020013278-A1 | Prodrug of an ice inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2002-01-31 | — | — | US | disclosed |
| WO-2001090063-A2 | PRODRUG OF AN ICE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048306-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20090012149-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20110301096-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20170022249-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20130331310-A1 | Prodrug of an Ice Inhibitor | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
| US-20020013278-A1 | Prodrug of an ice inhibitor | CASP1, MCL1, IL1A | CASP1 1/4885CASP4 280/4885CASP5 205/4885 |
| US-20150284426-A1 | PRODRUG OF AN ICE INHIBITOR | CASP1, MCL1, IL1B | CASP1 1/4885CASP4 260/4885CASP5 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.